NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy [ID690]

Please sign and return to:

Marcia Miller Technology Appraisal Administrator
Email: TACommA@nice.org.uk
Fax: +44 (0)20 7061 9721
Post: NICE, 10 Spring Gardens, London, SW1A 2BU

I confirm that:

- I agree with the content of the submission provided by **the British Society of Gastroenterology** and consequently I will not be submitting a personal statement.

Name: Dr Jeremy D Sanderson

Date: 10th November 2014.